Aakash Desai and Ahmed Ismail
Jun 22, 2025, 14:07
Aakash Desai and Ahmed Ismail Shared Review on HER2-altered NSCLC – From Biology and Testing to Advances In Treatment Modalities
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, posted on X:
“Just published!
Our review on HER2-altered NSCLC – from biology and testing to latest therapies.
Biomarker testing: tissue and ctDNA
ADCs and TKIs: T-DXd, zongertinib, A166, ARX788
Future: combo trials and next-gen agents.”
Ahmed Ismail, Former Research Fellow at the UAB O’Neal Comprehensive Cancer Center, shared a post by Aakash Desai on X, adding:
“I am so happy to see our review published in Frontiers in Oncology with my amazing mentors at the UAB O’Neal Comprehensive Cancer Center”
Title: HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities
Journal: Frontiers in Oncology
Authors: Ahmed Ismail, Desai Aakash, Yanis BoumberAhmed Ismail, Desai Aakash, Yanis Boumber
More posts featuring Aakash Desai on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 22, 2025, 13:52
Jun 22, 2025, 13:25
Jun 22, 2025, 11:44